Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

ABT — Abbott Laboratories

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 13.47%
Profit Margins 13.9%
Return on Equity 12.33%
Return on Assets 5.59%
Free Float 1.73B
Dividend Yield 2.68%
Short Int % Utilisation 1.41%

2.2 Growth

Metric Value
Revenue Growth 7.8%
Free Cash Flow 6.34B
EBITDA 15.56 (Ratio)
Enterprise Value 182.8B
EV/Revenue 4.05
EV/EBITDA 15.56

Revenue growth of 7.8% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* -10.65%
Risk / Std Dev (Ann.)* 26.46%
1-Year Price Return* -13.61%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $111.25
52-Week Range $81.97 – $137.49
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $44.33B $41.95B
Net income Reported net income $6.52B $13.40B
Total assets Year-end reported balance $86.71B $81.41B
Shareholders’ equity Year-end reported balance $52.13B $47.66B
Net margin Net income ÷ revenue 14.72% 31.95%
Asset turnover Revenue ÷ total assets 0.5112x 0.5153x
Equity multiplier Total assets ÷ shareholders’ equity 1.6634x 1.7081x
ROE Net margin × asset turnover × equity multiplier 12.51% 28.12%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $44.33B
Prior annual revenue $41.95B
EBIT $8.96B
Tax rate 22.90%
NOPAT = EBIT × (1 − tax rate) $6.91B
Forecast start-growth basis 5.67%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $6.91B
Add: depreciation & amortisation $3.12B
Less: capital expenditure -$2.17B
Less/(add): working-capital cash-flow movement -$803.00M
Current unlevered FCFF $7.05B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 5.67% $7.30B $3.29B -$2.29B -$848.52M $7.45B $7.18B
2 4.88% $7.65B $3.45B -$2.67B -$889.90M $7.55B $6.77B
3 4.08% $7.97B $3.59B -$3.05B -$926.24M $7.59B $6.32B
4 3.29% $8.23B $3.71B -$3.43B -$956.74M $7.55B $5.85B
5 2.50% $8.44B $3.81B -$3.81B -$980.66M $7.45B $5.37B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.58
Cost of equity 7.91%
Pre-tax cost of debt 3.41%
WACC 7.56%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $151.09B
Implied terminal EV / EBITDA 10.25x
Terminal value as % of enterprise value 76.92%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $31.50B
Present value of terminal value $104.96B
Indicated enterprise value $136.46B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $136.46B
Less: gross interest-bearing debt $13.86B
Add: cash and equivalents $8.94B
Add: affiliate investments $0.00
Less: minority interests $641.00M
Indicated common equity value $130.90B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 1,749,000,000.00
Share-count basis reported diluted weighted-average shares
Current market price $112.75
DCF indicative value per share $74.84
Indicative value vs. market price -33.62%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:20:31.938165 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -38.96% -28.71%
Adjusted R² 0.02 0.09
Annualised residual volatility 23.72% 22.72%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.16 (1.12) 0.48 (3.14)
Size (SMB) 0.30 (1.59) 0.34 (1.73)
Value (HML) 0.16 (1.00) -0.14 (-0.72)
Profitability (RMW) NM 0.60 (3.67)
Investment (CMA) NM 0.42 (1.50)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequityabthealth-carehealth-care-equipmentnasdaq